vs

Side-by-side financial comparison of Cheer Holding, Inc. (CHR) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Cheer Holding, Inc. is the larger business by last-quarter revenue ($71.0M vs $37.2M, roughly 1.9× Organogenesis Holdings Inc.). On growth, Cheer Holding, Inc. posted the faster year-over-year revenue change (-0.1% vs -57.1%).

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CHR vs ORGO — Head-to-Head

Bigger by revenue
CHR
CHR
1.9× larger
CHR
$71.0M
$37.2M
ORGO
Growing faster (revenue YoY)
CHR
CHR
+57.0% gap
CHR
-0.1%
-57.1%
ORGO

Income Statement — Q2 FY2025 vs Q1 FY2026

Metric
CHR
CHR
ORGO
ORGO
Revenue
$71.0M
$37.2M
Net Profit
$7.8M
Gross Margin
70.7%
30.8%
Operating Margin
11.7%
-185.1%
Net Margin
10.9%
Revenue YoY
-0.1%
-57.1%
Net Profit YoY
-37.5%
EPS (diluted)
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHR
CHR
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$225.6M
Q3 25
$150.9M
Q2 25
$71.0M
$101.0M
Q1 25
$86.7M
Q4 24
$126.7M
Q3 24
$115.2M
Q2 24
$71.1M
$130.2M
Net Profit
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
$43.7M
Q3 25
$21.6M
Q2 25
$7.8M
$-9.4M
Q1 25
$-18.8M
Q4 24
$7.7M
Q3 24
$12.3M
Q2 24
$12.4M
$-17.0M
Gross Margin
CHR
CHR
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
70.7%
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
73.4%
77.6%
Operating Margin
CHR
CHR
ORGO
ORGO
Q1 26
-185.1%
Q4 25
28.1%
Q3 25
13.7%
Q2 25
11.7%
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
16.4%
-10.7%
Net Margin
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
19.4%
Q3 25
14.3%
Q2 25
10.9%
-9.3%
Q1 25
-21.7%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
17.5%
-13.1%
EPS (diluted)
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$0.67
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$1.23
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHR
CHR
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$322.1M
Total Assets
$362.7M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHR
CHR
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$186.1M
$89.9M
Total Debt
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
$300.1M
Q3 25
$255.1M
Q2 25
$322.1M
$233.2M
Q1 25
$242.9M
Q4 24
$262.9M
Q3 24
$278.5M
Q2 24
$286.1M
$263.5M
Total Assets
CHR
CHR
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$598.7M
Q3 25
$509.8M
Q2 25
$362.7M
$461.1M
Q1 25
$467.4M
Q4 24
$497.9M
Q3 24
$446.3M
Q2 24
$333.2M
$443.2M
Debt / Equity
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHR
CHR
ORGO
ORGO
Operating Cash FlowLast quarter
$3.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
$39.4M
Q3 25
$3.1M
Q2 25
$3.9M
$-32.9M
Q1 25
$-19.9M
Q4 24
$10.9M
Q3 24
$8.7M
Q2 24
$-6.7M
$4.7M
Free Cash Flow
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
CHR
CHR
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
0.14×
Q2 25
0.51×
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
-0.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons